Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 142

Sort by

Sort Order Select

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

Takahiro Miyazaki, Saul Kivimäe, Marlene Hennessy, Rhoneil Pena, Phi Quach, Andrew Moffet, Wildaliz Nieves, Ping Zhang, Mario Q. Marcondes, MD PhD, Loui Madakamutil, Jonathan Zalevsky

Blood (2019) 134 (Supplement_1): 5302.

https://doi.org/10.1182/blood-2019-127771

Published: 2019

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Carissa Dege, PhD, Katherine H Fegan, MS, J Philip Creamer, IV, BA,BS, Melissa M Berrien-Elliott, PhD, Stephanie A. Luff, PhD, Julia A Wagner, PhD, Paul D. Kingsley, PhD, Kathleen E. McGrath, PhD, Todd A Fehniger, MD PhD, James Palis, MD, Christopher M. Sturgeon, PhD

Blood (2019) 134 (Supplement_1): 2464.

https://doi.org/10.1182/blood-2019-130347

Published: 2019

Journal Articles

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Xuan Guo, PhD, Srinivas Somanchi, PhD, Rohit Mathur, PhD, Shuyang He, PhD, Qian Ye, PhD, Andrea Difiglia, BS, Salvatore Rotondo, MS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 1576.

https://doi.org/10.1182/blood-2019-127009

Published: 2019

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma

Christine Bezombes, PhD, Cédric Rossi, MD, Pauline Gravelle, Julie Bordenave, Emilie Decaup, Mary Poupot, Marie Tosolini, Don-Marc Franchini, Camille Laurent, MD PhD, Renaud Morin, Jean-Michel Lagarde, Loic Ysebaert, MD PhD, Ariel Savina, Christian Klein, PhD, Patricia Perez-Galan, Jean-Jacques Fournié

Blood (2018) 132 (Supplement 1): 5381.

https://doi.org/10.1182/blood-2018-99-112404

Published: 2018

Journal Articles

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

Eric Robert Fedyk, PhD, Deborah Berg, RN, MSN, Glenda Smithson, PhD, Jose Estevam, Lachy Mclean, MD PhD, Kristina Allikmets, MD PhD, Antonio Palumbo, MD

Blood (2018) 132 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2018-99-112916

Published: 2018

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Carissa Dege, PhD, Kathleen E. McGrath, PhD, Melissa M Berrien-Elliott, PhD, Katherine H Fegan, MS, Julia Alexandra Wagner, BS, Todd A Fehniger, MDPhD, James Palis, MD, Christopher Sturgeon, PhD

Blood (2018) 132 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2018-99-119812

Published: 2018

Journal Articles

Ibrutinib in Combination with Anti-CD20-Antibody Negatively Affects Antibody Dependent Cellular Cytotoxic (ADCC) on Mantle Cell Lymphoma Cell Lines, Not Reversed By the Addition of Lenalidomide

Mats Jerkeman, MD PhD, Sara Ek, PhD, Catja Freiburghaus, PhD, Alexandra Albertsson Lindblad

Blood (2017) 130 (Supplement 1): 1266.

https://doi.org/10.1182/blood.V130.Suppl_1.1266.1266

Published: 2017

Journal Articles

Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells

Hiroyuki Takamatsu, MD PhD, Tatsuhiko Ozawa, PhD, Yoshitaka Zaimoku, MD, Akinori Tsuji, MD, Ichiro Hanamura, MD PhD, Junya Kuroda, MD PhD, Hidenori Tanaka, BS, Shintaro Kawai, PhD, Hiroyuki Kishi, PhD, Shinji Nakao, MD PhD

Blood (2017) 130 (Supplement 1): 2069.

https://doi.org/10.1182/blood.V130.Suppl_1.2069.2069

Published: 2017

Journal Articles

A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

Michelle Poon, Yeh Ching Linn, Noriko Shimasaki, Lip Kun Tan, Liang Piu Koh, Elaine Coustan-Smith, Dario Campana

Blood (2016) 128 (22): 3031.

https://doi.org/10.1182/blood.V128.22.3031.3031

Published: 2016

Journal Articles

CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model

Dirk Zboralski, Anna Kruschinski, Axel Vater

Blood (2016) 128 (22): 3021.

https://doi.org/10.1182/blood.V128.22.3021.3021

Published: 2016

Journal Articles

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Jörg Uwe Schmohl, MD, Martin Felices, PhD, Jeffrey S. Miller, MD, Dan Vallera, PhD

Blood (2016) 128 (22): 3518.

https://doi.org/10.1182/blood.V128.22.3518.3518

Published: 2016

Journal Articles

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

Zachary B. Davis, PhD BS, Todd Lenvik, Louis Hansen, Martin Felices, PhD, Sarah Cooley, MD, Dan Vallera, PhD, Ashley T. Haase, MD, Richard A. Koup, MD, Daniel Douek, MD, Timothy Schacker, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 2517.

https://doi.org/10.1182/blood.V128.22.2517.2517

Published: 2016

Journal Articles

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Beatrice Clemenceau, PhD, Thierry Guillaume, MD PhD, Nelly Robillard, PhD, Regine Vivien, Pierre Peterlin, MD, Alice Garnier, MD, Marie-Christine Bene, Henri Vié, PhD, Patrice Chevallier, MD PhD

Blood (2016) 128 (22): 5193.

https://doi.org/10.1182/blood.V128.22.5193.5193

Published: 2016

NARROW

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma Model

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Boosting Gamma Delta T Cells-Mediated ADCC By PD-1 Blockade in Follicular Lymphoma

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Ibrutinib in Combination with Anti-CD20-Antibody Negatively Affects Antibody Dependent Cellular Cytotoxic (ADCC) on Mantle Cell Lymphoma Cell Lines, Not Reversed By the Addition of Lenalidomide

Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells

A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only